(TR-987) - 药物靶点：TLR2_在研适应症：慢性静脉功能不全，静脉曲张溃疡_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Glucoprime、GLYC-101、MG-3601

+ [3]

靶点

TLR2

作用机制

TLR2调节剂(Toll样受体2调节剂)、巨噬细胞刺激剂

治疗领域

心血管疾病皮肤和肌肉骨骼疾病

在研适应症

慢性静脉功能不全静脉曲张溃疡

非在研适应症

创伤和损伤

原研机构

Kazia Therapeutics Ltd.

在研机构

Kazia Therapeutics Ltd.TR Therapeutics, Inc.

非在研机构

Glycotex, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

3

项与 TR-987 相关的临床试验

NCT03154619 / Active, not recruiting临床2期

Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial.

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

开始日期2016-11-01

申办/合作机构

SerenaGroup, Inc.

[+1]

NCT00792688 / Completed临床2期

Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 0.1% and 1.0% Topically Applied GLYC-101, Compared to Placebo, in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids.

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

开始日期2008-10-01

申办/合作机构

TR Therapeutics, Inc.

NCT00656474 / Completed临床1/2期

Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.

Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.

开始日期2008-03-01

申办/合作机构

TR Therapeutics, Inc.

100 项与 TR-987 相关的临床结果

登录后查看更多信息

100 项与 TR-987 相关的转化医学

登录后查看更多信息

100 项与 TR-987 相关的专利（医药）

登录后查看更多信息

100 项与 TR-987 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性静脉功能不全	临床2期	美国	TR Therapeutics, Inc.	2016-11-01
静脉曲张溃疡	临床2期	美国	-	2016-10-17
创伤和损伤	临床2期	美国	Glycotex, Inc.	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	临床2期	慢性静脉功能不全	82	TR987® 0.1% gel	觸網遞衊網糧積簾鏇窪(蓋醖鹹鏇餘製鬱衊鏇壓) = 餘鹽顧願醖廠糧憲繭醖觸糧築獵鏇膚網糧廠選 (壓鹹蓋齋製糧淵鑰觸糧 ) 更多	积极	2023-07-03
				Placebo gel	觸網遞衊網糧積簾鏇窪(蓋醖鹹鏇餘製鬱衊鏇壓) = 築願齋壓願鹽鑰夢範鏇觸糧築獵鏇膚網糧廠選 (壓鹹蓋齋製糧淵鑰觸糧 ) 更多
NCT00656474 (CTgov)	临床1/2期	创伤和损伤	12	GLYC-101 (GLYC-101 Active Retro-auricular Site (1 Per Participant))	製遞願廠鑰鬱網鏇襯獵(願衊鹽選淵選艱鑰鹽夢) = 糧構鑰糧願蓋鬱蓋襯艱膚夢繭廠選顧襯積糧鏇 (簾願醖衊選窪觸選艱顧, 選遞鹹範願憲鑰糧廠窪 ~ 積廠醖憲夢願糧窪衊夢) 更多	-	2011-07-25
				Placebo (Placebo Retro-auricular Site (1 Per Participant))	製遞願廠鑰鬱網鏇襯獵(願衊鹽選淵選艱鑰鹽夢) = 積遞蓋齋積衊簾憲鏇積膚夢繭廠選顧襯積糧鏇 (簾願醖衊選窪觸選艱顧, 膚積築簾窪積鑰艱艱窪 ~ 鏇襯觸築構願壓糧築壓) 更多